A carregar...
Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model
BACKGROUND: Omalizumab (trade name Xolair) is approved by the US Food and Drug Administration for treatment of moderate-to-severe allergic asthma. Given the high acquisition cost of omalizumab, its role and cost-effectiveness in disease management require definition. OBJECTIVE: We sought to identify...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2007
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3476046/ https://ncbi.nlm.nih.gov/pubmed/17904628 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2007.07.055 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|